Edition:
United Kingdom

BioScrip Inc (BIOS.OQ)

BIOS.OQ on NASDAQ Stock Exchange Global Select Market

2.22USD
14 Jun 2019
Change (% chg)

$0.02 (+0.91%)
Prev Close
$2.20
Open
$2.19
Day's High
$2.24
Day's Low
$2.18
Volume
125,984
Avg. Vol
295,526
52-wk High
$4.14
52-wk Low
$1.56

Latest Key Developments (Source: Significant Developments)

Bioscrip Quarterly Loss Per Share $0.14
Friday, 15 Mar 2019 

March 15 (Reuters) - BioScrip Inc ::BIOSCRIP REPORTS FOURTH QUARTER AND FULL YEAR 2018 FINANCIAL RESULTS.Q4 REVENUE $183.6 MILLION VERSUS REFINITIV IBES ESTIMATE OF $188.4 MILLION.SAYS PENDING COMBINATION ANNOUNCED WITH OPTION CARE, COMPANY WILL NOT BE PROVIDING UPDATED 2019 BIOSCRIP FINANCIAL GUIDANCE.QUARTERLY LOSS PER SHARE $0.14.Q4 EARNINGS PER SHARE VIEW $-0.03 -- REFINITIV IBES DATA.  Full Article

BioScrip And Option Care To Merge
Friday, 15 Mar 2019 

March 15 (Reuters) - BioScrip Inc ::PRESS RELEASE - HOME AND ALTERNATE SITE INFUSION THERAPY PROVIDERS BIOSCRIP AND OPTION CARE TO MERGE.BIOSCRIP INC - BIOSCRIP TO ISSUE NEW SHARES TO OPTION CARE'S SHAREHOLDER, WHICH WILL OWN APPROXIMATELY 80% OF COMBINED COMPANY ON FULLY DILUTED BASIS.BIOSCRIP INC - COMBINED COMPANY'S COMMON STOCK WILL CONTINUE TO BE LISTED ON NASDAQ GLOBAL MARKET.BIOSCRIP INC - TRANSACTION HAS BEEN UNANIMOUSLY APPROVED BY BOARDS OF DIRECTORS OF BOTH BIOSCRIP AND OPTION CARE.BIOSCRIP INC - COMBINED CO WILL BE LED BY OPTION CARE CHIEF EXECUTIVE OFFICER JOHN RADEMACHER AND OPTION CARE CHIEF FINANCIAL OFFICER MIKE SHAPIRO.BIOSCRIP INC - CO'S PRESIDENT AND CEO DANIEL E. GREENLEAF WILL REMAIN ACTIVE IN COMBINED CO AS A SPECIAL ADVISOR TO ITS BOARD OF DIRECTORS.BIOSCRIP - CO,OPTION CARE SECURED COMMITTED FINANCING FROM BANK OF AMERICA MERRILL LYNCH, FUNDS AFFILIATED WITH ARES MANAGEMENT, GOLDMAN SACHS MERCHANT BANKING DIVISION.BIOSCRIP - CO,OPTION CARE SECURED COMMITTED FINANCING TO REFINANCE & SIMPLIFY COMBINED CO'S CAPITAL STRUCTURE.BIOSCRIP - CO TO ISSUE NEW SHARES TO OPTION CARE'S SHAREHOLDER, OWNED BY INVESTMENT FUNDS RELATED TO MADISON DEARBORN PARTNERS, & WALGREENS BOOTS ALLIANCE.  Full Article

Bioscrip Reports Qtrly Loss Per Share $0.14
Tuesday, 7 Aug 2018 

Aug 7 (Reuters) - BioScrip Inc ::BIOSCRIP REPORTS SECOND QUARTER 2018 FINANCIAL RESULTS.Q2 REVENUE $175.8 MILLION VERSUS I/B/E/S VIEW $168.7 MILLION.SEES FY 2018 REVENUE $688 MILLION TO $698 MILLION.QTRLY LOSS PER SHARE $0.14.OPERATIONAL CASH FLOW IS EXPECTED TO RETURN TO MORE NORMALIZED LEVELS BEGINNING IN Q3 OF 2018.IMPLEMENTATION OF ASC 606 WILL NOT IMPACT OPERATING INCOME OR ADJUSTED EBITDA ON A GO-FORWARD BASIS.BIOSCRIP - REAFFIRMING 2018 GUIDANCE FOR REVENUE & ADJUSTED EBITDA.REMAIN INCREASINGLY CONFIDENT THAT CO CAN ACHIEVE AT LEAST $75 MILLION IN ADJUSTED EBITDA IN 2019.Q2 EARNINGS PER SHARE VIEW $-0.12 -- THOMSON REUTERS I/B/E/S.  Full Article

BioScrip Reports Qtrly Loss Per Share Of $0.12
Thursday, 10 May 2018 

May 10 (Reuters) - BioScrip Inc ::BIOSCRIP REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS.Q1 REVENUE $168.6 MILLION VERSUS I/B/E/S VIEW $165 MILLION.QTRLY LOSS PER SHARE $0.12.  Full Article

BioScrip Provides Update On Immaterial Financial Statement Corrections
Monday, 26 Mar 2018 

March 26 (Reuters) - BioScrip Inc ::BIOSCRIP TIMELY FILES ANNUAL FORM 10-K, CONCLUDES ACCOUNTING REVIEW AND PROVIDES UPDATE ON IMMATERIAL FINANCIAL STATEMENT CORRECTIONS.BIOSCRIP- FY2017 RESULTS REFLECT ANTICIPATED IMMATERIAL CORRECTIONS TO PRELIM FINANCIAL RESULTS REPORTED IN CO'S PRESS RELEASE DATED MARCH 8.  Full Article

BioScrip Announces Additions To Senior Leadership Team
Tuesday, 28 Nov 2017 

Nov 28 (Reuters) - BioScrip Inc ::BIOSCRIP ANNOUNCES ADDITIONS TO SENIOR LEADERSHIP TEAM.BIOSCRIP - ‍ANNOUNCED APPOINTMENTS OF HARRIET BOOKER AS CHIEF OPERATING OFFICER, DANNY CLAYCOMB AS SENIOR VICE PRESIDENT, REVENUE CYCLE MANAGEMENT​.  Full Article

Bioscrip reports qtrly ‍loss per share $0.12​
Thursday, 2 Nov 2017 

Nov 2 (Reuters) - Bioscrip Inc :Bioscrip reports third quarter 2017 financial results.Q3 revenue $198.7 million versus I/B/E/S view $200.9 million.Sees FY 2017 revenue $805 million to $810 million.Bioscrip Inc says ‍updated its adjusted EBITDA guidance to a range of $42.0 million to $44.0 million for full-year 2017​.Bioscrip Inc - Qtrly ‍loss per share $0.12​.Bioscrip Inc sees FY 2017 ‍loss per share in range of $0.58 to $0.64.FY2017 earnings per share view $-0.55, revenue view $824.5 million -- Thomson Reuters I/B/E/S.Q3 earnings per share view $-0.10 -- Thomson Reuters I/B/E/S.  Full Article